Patients treated with thinner artificial hair implants: a case series

Artificial biocompatible hair implants have been developed and clinically evaluated as a solution for hair loss, utilizing various materials and techniques to optimize safety, efficacy, and patient satisfaction. The primary objective of this study was to assess patient satisfaction in individuals affected by alopecia and treated with Biofibre^® 4.0, focusing on scalp hair density and aesthetic perception using a four-level evaluation scale. The secondary objective was to evaluate the rate of implanted hair loss at the one-year follow-up.

A total of 15 patients from different ethnicities were enrolled in the study, including 10 male and 5 female individuals. Biocompatible artificial hair with a diameter of 0.08 mm and a length between 160 and 460 mm (Biofibre^® 4.0, Medicap^®, Carpi, Italy) were utilized in the present study. The root of each fiber was positioned beneath the scalp, specifically at the level of the galea aponeurotica.

Biocompatibility was excellent, with no reported allergies or significant "foreign body" skin reactions. Analysis based on the primary effectiveness endpoint revealed a mean score of 3.1 on a 4-point grading scale, where 1 = not satisfied (one patient), 2 = somewhat satisfied (two patients), 3 = satisfied (seven patients), and 4 = very satisfied (five patients).

The implantation of new, thinner artificial hair fibers represents a valid and safe technique. Tolerability has improved due to the increased softness and elasticity of these fibers.

In conclusion, although the sample size is small, the results of this case series confirm the efficacy and safety of the new Biofibre^® 4.0 in the treatment of both male and female androgenetic alopecia (AGA), offering a well-tolerated and effective solution for improving aesthetic appearance and psychological well-being.